

## Special Issue

# Breast Cancer: New Diagnostic and Therapeutic Approaches

### Message from the Guest Editors

As the most diagnosed form of cancer worldwide, breast cancer (BC) represents a major health issue. In recent decades, researchers have intensively exploited next-generation sequencing (NGS) approaches to discover new actionable targets of breast tumor specimens, leading to the development of new therapy regimens (i.e., CDK4/6 inhibitors, PIK3CA inhibitors, etc.). More recently, novel approaches have been developed to improve cancer molecular characterization at epigenetic, transcriptomic, genetic and genomic levels. Moreover, the investigation of analytes retrievable in the peripheral blood (i.e., circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), etc.) has demonstrated an unprecedented potential to obtain further information concerning the core tumor. The topics of interest for this Special Issue can include, but are not limited to, the following:

- Prognostic and predictive biomarkers of breast cancer;
- Novel approaches to improve breast cancer characterization;
- Liquid biopsy in breast cancer;
- Genetic alterations in breast cancer

---

### Guest Editors

Dr. Erika Bandini

Dr. Tania Rossi

Dr. Sara Bravaccini

---

### Deadline for manuscript submissions

31 October 2025



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/211818](https://mdpi.com/si/211818)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).